Anti-CD19 CAR T cells potently redirected to kill solid tumor cells

Successful CAR T cell therapy for the treatment of solid tumors requires exemplary expansion, persistence and fitness, ability to target tumor antigens safely. Here we address this constellation critical attributes successful cellular by using integrated technologies that simplify development derisk clinical translation. We have developed a CAR-CD19 secretes CD19-anti-Her2 bridging protein. This strategy exploits CD19-targeting cells interact with CD19 on normal B drive fitness. The secreted protein potently binds Her2-positive cells, mediating cytotoxicity in vitro vivo . Because its short half-life, will selectively accumulate at site highest antigen expression, ie. tumor. Bridging proteins bind multiple different been created. Therefore, antigen-bridging incorporate therapy. platform can be exploited attack any cancer.